Hemoglobin >= . g/dL and no blood transfusions in the  days prior to entry/randomization
Hemoglobin >=  g/dL (blood transfusions are permitted for patients with hemoglobin levels below  g/dL) (within  days of treatment initiation)
Procurement: Hemoglobin (Hgb) > . g/dl (transfusions allowed)
Hemoglobin levels at the time of or within  days prior to transfusions must have been ? . g/dL for the transfusions to qualify as required for the purpose of providing evidence of transfusion-dependent anemia.
Hemoglobin (Hgb) >=  g/dL (may be achieved with erythropoietin agents; no blood transfusions in the  days prior to entry)
PROCUREMENT: Hemoglobin (Hgb) > . (transfusions allowed)
TREATMENT: Hgb > . g/dL (transfusions allowed)
Hemoglobin >=  g/dL\r\n* Note: Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier
Hemoglobin >=  g/dL performed within  days prior to the date of registration; no transfusions and erythropoietin supplementation permitted within the last  months
Hemoglobin greater than . mg/dl (transfusions are permitted to achieve baseline hemoglobin level), within  days prior to registration
Hemoglobin >= . g/dL (may receive transfusions)
Hemoglobin >=  g/dl (may receive transfusions)
INCLUSION CRITERIA FOR STRATUM C: Hemoglobin >=  g/dl (may receive transfusions)
Hemoglobin >=  g/dL (transfusions are permissible)
Hemoglobin >=  g/dL (transfusions allowed)
Hemoglobin >=  g/dL, with no blood transfusions in the  days prior to study entry
Within  days prior to administration of study treatment: Hemoglobin >= . g/dL (unless due to bone marrow infiltration by tumor, in which case hemoglobin >=  g/dL is allowed) and no blood transfusions in the  days prior to entry.
Hemoglobin >=  g/dL (transfusions permitted)
Within  days prior to registration: Hemoglobin >= . mg/dl (transfusions are permitted to achieve baseline hemoglobin level)
Hemoglobin >=  g/dL; RBC transfusions and use of G-CSF will be allowed in order to meet eligibility parameters (unless dysfunction is secondary to lymphoma involvement)
Hemoglobin ? . g/dL (may receive transfusions)
Hemoglobin ?  g/dL (transfusions are allowed)
Hemoglobin >=  g/dl (no blood transfusions within  weeks prior to enrollment)
hemoglobin ? . g/dL (transfusions permissible)
Hemoglobin (Hgb) >=  g/dL without transfusions
CAPMATINIB INCLUSION CRITERIA: Hemoglobin >=  g/dL (transfusions are allowed)
CERITINIB INCLUSION CRITERIA: Hemoglobin >=  g/dL (transfusions are allowed)
ENTRECTINIB INCLUSION CRITERIA: Hemoglobin >=  g/dL (transfusions are allowed)
Hemoglobin > g/dL (may receive transfusions).
Hemoglobin (Hgb) >=  g/dL (transfusions allowed)
Hemoglobin >= . g/dL and no blood transfusions in the  days prior to enrollment
PROCUREMENT: Hemoglobin (Hgb) > . (transfusions allowed)
Hemoglobin >=  g/dl (may receive transfusions)
Hemoglobin (Hgb) ?  g/dL. NOTE: subject must not have received any growth factor or blood transfusions within  days prior to the hematology values obtained at screening. Subjects requiring transfusions to meet eligibility criteria are not eligible.
Hemoglobin at least . grams per deciliter (g/dL) at Baseline (blood transfusions are allowed during the screening period to correct hemoglobin values less than . g/dL) As blood transfusions are permitted to meet the hemoglobin criteria, participants requiring transfusion must not be known to be refractory to red blood cell or platelet transfusions.
Hemoglobin (Hgb) >=  g/dL without transfusions
Hemoglobin >=  g/dL (may receive transfusions)
To be performed within  days prior to day  of protocol therapy: Hemoglobin (Hgb) >=  g/dL without transfusions
Hemoglobin >=  g/dL (transfuse as necessary to raise levels, no transfusions within  days of start)
Hemoglobin greater than  g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin (Hgb) >= . g/dL (transfusions allowed)
Hemoglobin >=  g/dL\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
Hemoglobin >=  g/L\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
Hemoglobin >=  g/dL (prior to transfusions)
Hemoglobin >=  g/dL (transfusions are acceptable)
Hemoglobin >=  g/dL (transfusions are not permissible)
Hemoglobin >=  g/dL (may receive transfusions)
Hemoglobin >=  g/dL (transfusions allowed)
Hemoglobin >= . g/dL (not requiring transfusions within the past  weeks)
Hemoglobin >=  g/dL\r\n* Transfusions and erythropoietin supplementation permitted
Hemoglobin (Hgb) greater than or equal to  g/dL (transfusions are allowed)
Hemoglobin value >=  g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >=  g/dL with blood transfusions are allowed)
Hemoglobin value >=  g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >=  g/dL with blood transfusions are allowed)
Subjects must be willing to accept/continue transfusions to treat low hemoglobin levels
Hemoglobin >= . g/dL not requiring transfusions within the past  weeks
Within  weeks of randomization: Hemoglobin value >=  g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >=  g/dL with blood transfusions are allowed)
History of  to  PRBC transfusions
Hemoglobin (Hgb) >=  g/dL without transfusions
Participants requiring blood transfusions to maintain hemoglobin (Hgb) eligibility
TREATMENT: Hemoglobin greater than  g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin >=  g/dL (transfusions are permissible)
Hemoglobin >= . g/dL (may receive transfusions)
Hemoglobin >= . mmol/L or  g/dL; up to % deviation is tolerated; transfusions and growth factors are allowed
Hemoglobin (Hgb) >=  g/dL without transfusions
Hematologic: Absolute neutrophil count > . x /L, platelets >  x /L, hemoglobin ?  g/dL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. The first dose of study drug must not begin until  days after the erythrocyte transfusion);
Hemoglobin >= . g/dL (not requiring transfusions within the past  weeks)
Hemoglobin (Hb) >= g/dL (women) or >= g/dL (men) (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)
Hemoglobin >=  g/dL (with transfusions)
Hemoglobin ?  g/dL (transfusions are allowed)
Hemoglobin >= . g/dL not requiring transfusions within the past  weeks
Hemoglobin >  g/dL (transfusions allowed)
Hemoglobin greater than g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin (Hgb) >=  g/dL without transfusions
Hemoglobin >  g/dL (international system [SI] units:  g/L); patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion
Hemoglobin >  mg/dl; Physician can maintain a patient's hemoglobin with the use of erythropoietin or transfusions (prophylactic use of G-CSF [filgrastim] is not permitted)
Hemoglobin >=  g/dL (transfusions and/or erythropoietin are permitted)
Hemoglobin ? g/dL (? g/L) Note that transfusions are allowed to meet the required hemoglobin level
